US Market News
5日前
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 MillionJune 9, 2026 7:45 AM
Business Wire Transaction values Ignite Proteomics at approximately $150 million and is expected to position Ignite as an independent NYSE-listed functional proteomics company, while Aditxt continues as a separate Nasdaq-listed company Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics, LLC (“Ignite”, or “Ignite Proteomics”), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement. The transaction values Ignite at an implied equity value of approximately $150 million, subject to the terms and conditions of the business combination agreement. Upon closing, Ignite is expected to separate from Aditxt and become an independent publicly traded company through a newly formed public holding company expected to be named Ignite Proteomics , Inc. (“Ignite Holdings, Inc.,” or “Pubco”). Following closing, the acquisition corp. and Ignite are expected to become wholly owned subsidiaries of the newly formed public holding company. Pubco’s common stock and public warrants are expected to be listed on the New York Stock Exchange, subject to approval of the listing application and satisfaction of customary closing conditions. For Aditxt, the transaction is expected to unlock value in its 100%-owned Ignite subsidiary while allowing Aditxt to continue operating as a separate Nasdaq-listed public company, subject to continued compliance with Nasdaq listing requirements. Strategic Value Creation for Aditxt Aditxt acquired Ignite as part of its strategy to identify, acquire and advance differentiated health innovation platforms. The proposed business combination is intended to provide Ignite with a dedicated public-company platform, greater visibility and access to growth capital, while highlighting the value of Ignite within Aditxt’s portfolio. “Today’s announcement represents an important milestone for Aditxt and Ignite,” said Jeff Busch, Interim Chief Executive Officer of Aditxt and Chief Executive Officer of Ignite Proteomics. “Aditxt owns 100% of Ignite, a differentiated precision oncology asset, and this transaction is expected to unlock that value through a business combination that values Ignite at approximately $150 million. At the same time, Aditxt is expected to continue as a separate Nasdaq-listed company focused on advancing its broader health innovation strategy.” Mr. Busch continued, “For Ignite, becoming an independent public company is expected to provide the focus, visibility and access to capital needed to accelerate commercialization, expand clinical evidence generation and pursue broader adoption of its functional proteomics platform in oncology.” Advancing Functional Proteomics in Precision Oncology Ignite is developing and commercializing a functional proteomics platform designed to help physicians better understand the biological activity driving a patient’s tumor. Unlike traditional approaches that may infer protein activity from genomic information, Ignite’s platform is designed to directly measure protein and phosphoprotein signaling activity from tumor tissue, providing a functional view of tumor biology that may support more informed therapy selection. Ignite’s current commercial focus is in breast cancer, with a broader development strategy intended to support expansion into additional tumor types and treatment settings over time. The company believes its platform may be particularly relevant as oncology treatment continues to shift toward increasingly targeted therapeutic classes, including antibody-drug conjugates, immunotherapies and targeted therapies. Platform Positioned for Commercial and Clinical Expansion Ignite’s growth strategy is expected to focus on expanding clinical adoption, scaling commercial operations, supporting additional clinical evidence generation and pursuing collaborations with academic institutions, oncology networks, payors and biopharmaceutical partners. Net proceeds from the transaction, including cash remaining in the acquisition corp trust account after redemptions and any additional transaction financing, are expected to support Ignite’s commercialization initiatives, clinical evidence generation, working capital needs and general corporate purposes. Transaction Overview The transaction is expected to result in Ignite becoming an independent publicly listed company through a business combination with the acquisition corp. Following closing, the acquisition corp. and Ignite are expected to become wholly owned subsidiaries of a newly formed public holding company. The transaction values Ignite at an implied equity value of approximately $150 million, with Ignite equity holders expected to receive newly issued shares of Pubco common stock based on a $10.00 per share reference price, subject to the terms and conditions of the business combination agreement. The boards of directors / managers of the applicable parties have approved the transaction. Closing is subject to customary conditions, including approval by acquisition corp. shareholders, approval by Ignite equity holders, effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission, approval for listing of Pubco’s common stock and public warrants on the NYSE, satisfaction of applicable regulatory and third-party consent requirements, and satisfaction of minimum cash / financing conditions. Following closing, the combined company is expected to be led by Ignite’s management team. Pubco’s board of directors is expected to consist of seven directors designated by Ignite, including a majority of independent directors. About Ignite Proteomics Ignite Proteomics is a functional proteomics company focused on advancing precision oncology through direct measurement of protein expression and pathway activation. The company’s Reverse Phase Protein Array platform is designed to measure functional protein and phosphoprotein activity from tumor tissue to support therapy-selection insights across oncology. Ignite’s current commercial focus is in breast cancer, with a broader development strategy intended to support future expansion into additional tumor types, therapeutic classes and data-driven clinical applications. For more information, visit https://igniteproteomics.com/ About Aditxt, Inc. Aditxt, Inc. (NASDAQ: ADTX) is a public company focused on developing and commercializing health innovation platforms. Ignite Proteomics is currently a 100%-owned subsidiary of Aditxt. Through the proposed business combination, Aditxt expects to unlock value in Ignite at an implied equity value of approximately $150 million, while Ignite is expected to become an independent publicly traded company. Aditxt is expected to continue as a separate Nasdaq-listed public company, subject to continued compliance with Nasdaq listing requirements. About the Acquisition Corp The undisclosed acquisition corp is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Advisors Ladenburg Thalmann & Co. Inc. is serving as financial advisor to the newly formed public holding company and Ignite Proteomics, LLC, and Meister Seelig & Schuster PLLC is serving as legal counsel. Additional Information and Where to Find It In connection with the proposed transaction, Pubco intends to file with the SEC a registration statement on Form S-4, which will include a proxy statement / prospectus of the acquisition corp. and Pubco. The acquisition corp., Pubco, Aditxt and Ignite urge investors, shareholders and other interested persons to read, when available, the preliminary and definitive proxy statement / prospectus, as well as other documents filed with the SEC, because these documents will contain important information about the acquisition corp., Pubco, Aditxt, Ignite and the proposed transaction. Investors and security holders will be able to obtain free copies of the proxy statement / prospectus and other documents filed with the SEC by the acquisition corp, Pubco, Aditxt and Ignite through the website maintained by the SEC at www.sec.gov. Participants in the Solicitation The acquisition corp., Pubco, Aditxt, Ignite and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the acquisition corp. shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of the acquisition corps shareholders in connection with the proposed transaction will be set forth in the registration statement / proxy statement / prospectus when filed with the SEC. No Offer or Solicitation This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote, consent or approval, in any jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of applicable securities laws. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the proposed business combination, the anticipated benefits of the transaction, the expected separation of Ignite from Aditxt, the expected listing of the combined company’s securities on the NYSE, the implied equity value of Ignite, Aditxt’s expected continued Nasdaq listing, expected use of proceeds, Ignite’s business strategy, clinical and commercial expansion plans, and the timing and ability of the parties to consummate the transaction. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including risks related to the parties’ ability to satisfy closing conditions, obtain required shareholder and regulatory approvals, complete any contemplated financing, satisfy NYSE and Nasdaq listing requirements, satisfy continued Nasdaq listing requirements applicable to Aditxt, and execute their respective business and commercialization strategies. The parties undertake no obligation to update any forward-looking statements, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260608697723/en/ Media Contact:
IR@aditxt.com Original: Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
US Market News
2週前
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to ShareholdersJune 1, 2026 8:15 AM
Business Wire Seasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven growth. Aditxt, Inc. (Nasdaq: ADTX)(“Aditxt” or the “Company”), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision oncology diagnostics subsidiary Ignite Proteomics, LLC (“Ignite”) since March 2026, will now lead the full Aditxt enterprise as it executes an accelerated commercialization strategy centered on Ignite's precision oncology diagnostics platform. Mr. Busch simultaneously continues in his role as CEO of Ignite. The Board of Directors expressed its deep appreciation for the contributions of outgoing CEO Amro Albanna, who resigned as CEO, from the Company’s Board and from all positions with the Company’s subsidiaries. Mr. Albanna co-founded Aditxt and led the Company through its founding vision, public listing, and acquisition strategy, including the addition of Ignite to the Aditxt portfolio. Mr. Albanna's scientific conviction and entrepreneurial persistence established the foundation upon which the Company's next chapter will be built. The Board wishes him well in his future endeavors. "Jeff brings exactly the combination of skills this moment requires: public company leadership, capital markets credibility, deep healthcare-sector expertise, and a track record of building shareholder value in a regulated, mission-driven environment. We are confident that under his leadership, Aditxt will accelerate the commercial trajectory of Ignite Proteomics while ensuring that every decision reflects our responsibility to patients, partners, employees, and investors alike." — Brian Brady, Chairman of the Board, Aditxt, Inc. About Jeffrey M. Busch Mr. Busch is the Founder, Chairman, and former Chief Executive Officer of Global Medical REIT, Inc. (NYSE: GMRE), now Chiron Real Estate, Inc. (NYSE: XRN), an NYSE-listed net-lease healthcare real estate investment trust that he founded and built to over $1 billion in enterprise value. Throughout his tenure as CEO, Mr. Busch maintained a consistent and disciplined dividend program, delivering an average annual dividend yield of approximately 8.5% to common shareholders — a track record that reflects both his commitment to capital stewardship and his ability to build institutional-grade infrastructure within a regulated, healthcare-focused business environment. A graduate of the New York University Stern School of Business with a Bachelor of Science in Business, Mr. Busch also holds a Master of Public Administration specializing in health policy from New York University and a Juris Doctor from Emory University. His academic foundation spans law, business, and health policy — a rare combination that has informed both his regulatory approach and his commercial strategy throughout a career at the intersection of healthcare and capital markets. Earlier in his career, Mr. Busch served as a congressional aide before being appointed by two United States Presidents to serve in their administrations, including as a United States Delegate to the United Nations in Geneva. Since 2001, he has served as President of the Safe Blood International Foundation, overseeing the establishment of medical facilities in 35 developing nations — programs funded by the CDC, USAID, ExxonMobil, and the Gates Foundation. This global health mission underscores a career defined not only by financial performance, but by a genuine commitment to expanding access to life-saving medical care. "Aditxt and Ignite sit at one of the most important intersections in modern medicine — precision diagnostics and patient-centered oncology care. With approximately 40% of cancer drugs not working for the patients they are prescribed to, the clinical imperative behind what Ignite does could not be more clear. My focus will be on translating that clinical imperative into a commercially excellent, financially disciplined, and patient-first organization. We have a Medicare-reimbursed platform, growing clinical validation, established research partnerships, and a large and expanding addressable market. The work ahead is to build on that foundation with urgency and accountability — to our patients, to our people, and to our shareholders." — Jeffrey M. Busch, Interim Chief Executive Officer, Aditxt, Inc. Strategic Priorities Under New Leadership Under Mr. Busch's leadership, Aditxt intends to advance the following core strategic priorities: Patients First, Always. Every strategic and operational decision will be evaluated against a single standard: “does it serve patients and improve their lives?” This commitment is non-negotiable and will govern the Company's culture, capital allocation, and commercial behavior. Revenue-Driven Innovation. Aditxt will pursue clinical innovation and commercial performance with equal discipline — deepening the clinical evidence base that supports Ignite's RPPA platform while simultaneously building the revenue infrastructure necessary to fund continued R&D and sustain the Company's mission long-term. Responsibility to All Stakeholders. The Company will operate with full transparency and financial discipline — meeting its obligations to employees, clinical partners, vendors, and shareholders, and building an organization worthy of the trust placed in it by every constituency it serves. Capital Market Engagement. Drawing on Mr. Busch's experience building and sustaining an NYSE-listed public company, Aditxt will pursue proactive investor relations, responsible capital stewardship, and strategic partnership development to support the Company's growth trajectory and enhance long-term shareholder value. About Aditxt, Inc. Aditxt, Inc. (Nasdaq: ADTX) is a life sciences platform company focused on accelerating promising health innovations. Through its subsidiary Ignite Proteomics, Aditxt operates a CLIA-certified precision oncology diagnostics laboratory that uses Reverse Phase Protein Array (RPPA) technology to help physicians identify the most effective cancer treatment for each individual patient. Ignite holds a Medicare PLA code and has established clinical collaborations with leading cancer research institutions including Dana-Farber Cancer Institute and Vanderbilt University Medical Center. About Ignite Proteomics Ignite Proteomics is a CLIA-certified precision oncology diagnostics company utilizing proprietary Reverse Phase Protein Array (RPPA) technology to deliver functional protein-level analysis that guides cancer treatment selection. With Medicare reimbursement established through a dedicated PLA code and growing clinical validation across multiple cancer types, Ignite is positioned to address one of oncology's most persistent challenges: ensuring that the right patient receives the right therapy at the right time. Important Note Regarding Historical Dividend References References in this press release to dividend yield, dividend history, enterprise value, capital stewardship, shareholder value creation, or other historical performance metrics relate solely to Mr. Busch’s prior service at Global Medical REIT, Inc., now Chiron Real Estate, Inc., and are provided only as biographical background regarding Mr. Busch’s prior professional experience. Such references do not relate to Aditxt, Inc. and should not be understood as a statement, projection, forecast, commitment, or indication that Aditxt intends to declare, pay, initiate, maintain, or recommend dividends or any other distributions to stockholders. Aditxt does not currently have a dividend policy and has no current plan or intention to declare or pay cash dividends or other distributions to stockholders. Any future determination regarding dividends, if ever considered, would be subject to the discretion and approval of Aditxt’s Board of Directors and would depend on, among other things, Aditxt’s financial condition, operating results, capital requirements, liquidity, contractual restrictions, applicable law, and other factors the Board may deem relevant. Investors should not infer from Mr. Busch’s prior experience at another public company that Aditxt will adopt any similar dividend, capital allocation, financing, investor relations, or shareholder return strategy. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements include all statements other than statements of historical fact, including, without limitation, statements regarding Aditxt, Inc.’s expectations, plans, objectives, strategy, priorities, business outlook, leadership transition, anticipated benefits of the appointment of Jeffrey M. Busch as Interim Chief Executive Officer, the expected impact of Mr. Busch’s prior public company, healthcare, capital markets, operational, commercial, and strategic experience, Aditxt’s ability to advance, commercialize, grow, finance, scale, or otherwise realize value from Ignite Proteomics or any of Aditxt’s other businesses, assets, subsidiaries, platforms, technologies, products, services, intellectual property, collaborations, clinical initiatives, regulatory strategies, reimbursement opportunities, market opportunities, investor relations initiatives, capital markets activities, strategic partnerships, or other corporate objectives. Forward-looking statements may include words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “pursue,” “seek,” “should,” “target,” “will,” “would,” “accelerate,” “advance,” “build,” “commercialize,” “expand,” “enhance,” “execute,” “grow,” “improve,” “lead,” “support,” “transform,” and similar words, phrases, or expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements regarding Aditxt’s expectations concerning its new leadership structure; the Company’s ability to transition successfully following the appointment of a new Interim Chief Executive Officer; the ability of the new Interim Chief Executive Officer to implement any strategic, operational, commercial, financing, investor relations, capital allocation, or other initiatives; the Company’s ability to execute an accelerated commercialization strategy centered on Ignite Proteomics; the potential clinical utility, commercial opportunity, market demand, reimbursement potential, revenue potential, scalability, validation, adoption, or competitive position of Ignite’s precision oncology diagnostics platform, including its Reverse Phase Protein Array technology; the Company’s ability to maintain, utilize, expand, or benefit from CLIA certification, Medicare reimbursement, PLA coding, clinical collaborations, research partnerships, institutional relationships, or other commercial or regulatory infrastructure; the Company’s ability to generate revenue, improve financial discipline, satisfy obligations to employees, vendors, clinical partners, investors, creditors, or other stakeholders, or create or enhance long-term stockholder value; and any statements concerning patients, partners, employees, investors, capital markets engagement, commercial discipline, transparency, accountability, stakeholder responsibility, addressable market, clinical need, or future growth. Historical references in this press release to Mr. Busch’s prior professional experience, including references to enterprise value, dividend yield, dividend programs, capital stewardship, shareholder value, public company leadership, healthcare-sector experience, capital markets experience, or the performance, strategy, capital allocation, financing, dividend history, investor relations, or stockholder return profile of any company with which Mr. Busch was previously affiliated, are provided solely for biographical and background purposes. Such references are not predictions, projections, guarantees, or indications of Aditxt’s future performance, strategy, financial results, stock price, market capitalization, enterprise value, capital allocation, financing activities, investor relations activities, dividend policy, or stockholder returns. Aditxt does not currently have a dividend policy and has no current plan or intention to declare or pay dividends or other distributions to stockholders. Any future dividend or distribution, if ever considered, would be subject to the discretion and approval of Aditxt’s Board of Directors and would depend on numerous factors, including Aditxt’s financial condition, operating results, liquidity, capital requirements, contractual restrictions, applicable law, and other considerations the Board may deem relevant. Investors should not place undue reliance on historical biographical information regarding Mr. Busch’s prior experience or infer that Aditxt will adopt, implement, or achieve similar results, dividend practices, capital allocation strategies, financing strategies, or shareholder return outcomes. Forward-looking statements are based on current expectations, estimates, assumptions, beliefs, and information available to Aditxt as of the date of this press release. These statements are subject to significant risks, uncertainties, and other factors, many of which are outside Aditxt’s control, that could cause actual results, performance, achievements, events, or circumstances to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, risks related to Aditxt’s liquidity, capital resources, ability to continue as a going concern, ability to obtain additional financing on acceptable terms or at all, ability to satisfy existing and future obligations, ability to maintain compliance with Nasdaq listing standards, ability to manage leadership transitions, ability to retain and motivate key personnel, ability to execute its business strategy, ability to commercialize or generate revenue from Ignite Proteomics or any other business line, ability to maintain regulatory, laboratory, reimbursement, clinical, commercial, vendor, employee, and strategic relationships, market acceptance of its products and services, competition, intellectual property protection, regulatory developments, healthcare reimbursement, clinical validation, operational execution, macroeconomic conditions, capital markets conditions, and other risks described in Aditxt’s filings with the Securities and Exchange Commission, including Aditxt’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other SEC filings. Forward-looking statements speak only as of the date they are made. Aditxt undertakes no obligation to update, revise, or publicly release any update or revision to any forward-looking statement, whether as a result of new information, future events, changes in expectations, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on any forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20260601699250/en/ Investor Relations
IR@aditxt.com
www.aditxt.com Original: Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders
US Market News
2月前
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer PatientsApril 20, 2026 8:15 AM
Business Wire
Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite’s platform — the only commercially available multiplex assay in the study—demonstrates predictive value for patient outcomes
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd, marketed as Enhertu® by AstraZeneca and Daiichi Sankyo) and assessed multiple quantitative HER2-related assays for their association with treatment outcomes.
While conventional HER2 immunohistochemistry (IHC) showed some association with outcomes in the broader patient population, the study found that quantitative HER2-related assays provided more granular predictive information in several matched biomarker sub-cohorts. In those sub-cohorts, traditional IHC classification often showed limited predictive value compared with quantitative approaches. Ignite’s Reverse Phase Protein Array (RPPA) platform, the only commercially available multiplex assay in the study, was one of the quantitative methods that demonstrated meaningful predictive value for patient outcomes.
T-DXd is an approved treatment option for a broad population of patients with metastatic breast cancer, yet there is currently no reliable way to predict which patients will respond.
“According to several studies, approximately 40% of cancers do not respond to the FDA approved therapy at front line in a metastatic setting,” said Jeff Busch, Chief Executive Officer of Ignite Proteomics. In oncology, published research and institutional analyses have shown that approved therapies often fail to benefit a substantial portion of the patients who receive them. A 2017 study published in the BMJ reported that 57% of cancer drug indications approved by the European Medicines Agency entered the market without evidence of improved survival or quality-of-life benefit. MIT researchers have noted that targeted tyrosine kinase inhibitors typically work for only 40% to 80% of patients expected to respond. Johns Hopkins has reported that only 15% to 20% of patients achieve durable results with immunotherapy.
Ignite’s RPPA platform measures multiple protein biomarkers, including pathway activation and payload-relevant markers, from a single tumor sample. In the Dana-Farber study, Ignite’s platform was the only commercially available multiplex assay evaluated and demonstrated predictive value in matched biomarker cohorts where conventional HER2 IHC showed limitations. Notably, the study found that TOPO1 expression, the target of T-DXd’s cytotoxic payload, was detectable by Ignite’s platform in certain HER2-negative patients, highlighting the potential value of measuring tumor biology beyond HER2 expression alone. Ignite’s assay is CLIA-certified, CAP-accredited, listed on the Medicare Clinical Laboratory Fee Schedule under AMA CPT code PLA 0249U, and orderable today on standard biopsy tissue.
“Cancer therapy has made extraordinary progress, but oncology still has a treatment-selection problem,” added Busch. “Too many patients receive therapies without enough information about whether those therapies are likely to work for their tumor biology. That is not an indictment of the drugs. These are powerful therapies. The issue is that cancer is complex, and single-marker testing often does not capture the functional biology that drives response or resistance. Ignite’s RPPA platform was built to address that gap by measuring multiple proteins, pathway activation, and payload-relevant biology from the same tumor sample. In this study, one of the world’s leading breast cancer research teams evaluated our platform alongside standard testing, and our platform demonstrated predictive value where conventional testing had limitations. That is the opportunity: better data, better treatment selection, and fewer patients receiving therapies that were never likely to help them.”
“This publication represents an important milestone for our subsidiary Ignite and reflects the strength of Aditxt’s model of advancing and scaling impactful health innovations,” said Amro Albanna, Co-Founder and Chief Executive Officer of Aditxt. “Peer-reviewed clinical evidence from one of the world’s leading cancer research institutions is key to accelerating the commercialization of this platform and expanding access to it for millions of patients making treatment decisions without clear guidance on what will work. Our goal is to help ensure that more patients receive the right therapy at the right time, with the potential to improve outcomes and make a meaningful difference in people’s lives.”
The full study is available open access at: https://doi.org/10.1038/s41698-026-01365-6
About Ignite Proteomics, LLC
Ignite Proteomics delivers pathway-level protein analytics to guide precision oncology. Operating a CLIA-certified, CAP-accredited laboratory, Ignite's clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from limited biopsy material to support oncology research and clinical decision making.
About Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "believe," "could," "expect," "intend," "may," "plan," "potential," "seek," "will," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the significance of the published study, Ignite’s commercialization plans, the potential clinical utility of its platform, expected collaborations, publications, reimbursement, adoption, and international expansion. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company’s SEC filings, including Aditxt’s Annual Report on Form 10-K and any subsequent Form 10-Q filings, including the most recent filed on November 18, 2025. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260420307974/en/
Aditxt, Inc.
Investor Relations
ir@aditxt.com
Original: Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
US Market News
3月前
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive OfficerMarch 19, 2026 8:15 AM
Business Wire
Busch brings public company leadership and capital markets experience to support Ignite’s next phase of growth
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”).
Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most likely to work for each patient.
Mr. Busch is the Founder, Chairman, and former Chief Executive Officer of Chiron Real Estate Inc. (NYSE: XRN), formerly Global Medical REIT (NYSE: GMRE), a company he founded, bringing public company leadership and capital markets experience to Ignite.
As CEO, Mr. Busch will lead Ignite’s commercial expansion and help evaluate strategic growth and financing alternatives as the company advances its business plan.
“Ignite sits at the intersection of real clinical demand and compelling growth opportunity,” said Jeff Busch, Chief Executive Officer of Ignite Proteomics. “We have a commercial-stage platform, Medicare reimbursement, growing clinical validation, and a large addressable market. With approximately 40% of cancer drugs not working for the patients they are prescribed to, Ignite’s assay is designed to help physicians identify the right drug for the right patient at the right time. My focus is disciplined execution — scaling revenue responsibly while building a company capable of generating sustainable profitability. The objective is clear: create durable public market equity value and structured cash flow that benefits Ignite, Aditxt, and its shareholders.”
“This appointment reflects the continued execution of Aditxt’s Discovery, Development and Deployment model,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. “Jeff brings public company leadership and strategic growth experience that we believe will support Ignite’s next phase of development. We look forward to partnering with him and his team to support Ignite’s growth. Our objective is to build platforms that advance health innovations while delivering long-term value for Aditxt and its shareholders.”
Jeff Busch Biography
Jeff Busch is the Chief Executive Officer of Ignite Proteomics, a subsidiary of Aditxt, Inc. Mr. Busch is the Founder, Chairman, and former Chief Executive Officer of Chiron Real Estate, Inc. (NYSE: XRN), formerly Global Medical REIT (NYSE: GMRE), and has extensive experience in public company leadership, capital markets and healthcare-related businesses.
Mr. Busch holds a Bachelor of Science in Business and a Master of Public Administration specializing in health policy from New York University, as well as a Juris Doctor from Emory University. Earlier in his career, he served as a congressional aide and was later appointed by two United States Presidents to serve in their administrations, including as a delegate to the United Nations in Geneva.
About Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health.
Forward-Looking Statements
This press release includes “forward-looking statements,” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “aim,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “will,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding Ignite Proteomics’ commercial expansion, strategic growth and financing opportunities, the anticipated benefits of Jeff Busch’s appointment as Chief Executive Officer, and Aditxt’s plans and expectations with respect to Ignite’s development. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company’s SEC filings, including Aditxt’s Annual Report on Form 10-K and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260319940379/en/
Aditxt, Inc.
Investor Relations
ir@aditxt.com
Original: Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
US Market News
3月前
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy SelectionMarch 13, 2026 8:15 AM
Business Wire
Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone.
Aditxt Co-Founder and Chief Executive Officer Amro Albanna stated: “Each year nearly 20 million people are diagnosed with cancer worldwide, tens of millions undergo treatment, and millions of patients with advanced disease ultimately face limited therapeutic options. These realities underscore the importance of improving how therapies are selected, particularly as precision medicines increasingly depend on identifying whether a patient’s tumor expresses the intended biological targets for those therapies. We believe there is a real need for tools that can provide physicians with additional information to help support more informed treatment decisions, particularly as targeted therapies become more precise and more complex.”
Albanna continued, “This acquisition reflects the continued execution of our Discovery, Development, and Deployment model, which is focused on identifying and advancing companies addressing important challenges in healthcare. We believe Ignite adds a differentiated platform to our oncology efforts at a time when treatment selection and longitudinal monitoring are becoming increasingly important in cancer care.”
According to third-party market research, the global cancer profiling market is estimated at approximately $14 billion (Source: Mordor Intelligence). Ignite estimates approximately $3 billion of serviceable opportunity among patients eligible for antibody drug conjugate (ADC) therapies and other targeted cancer treatments. The continued expansion of targeted cancer therapies and antibody drug conjugates is increasing the demand for tools that can determine whether a patient’s tumor expresses the functional protein targets these therapies require.
Ignite operates a CLIA-certified laboratory and has an established Medicare Proprietary Laboratory Analyses (PLA) reimbursement pathway of approximately $2,200 per test. This commercial foundation distinguishes it from many earlier-stage diagnostics companies. The platform is designed to support both therapy selection and longitudinal monitoring as precision medicines increasingly require ongoing response assessment.
Ignite plans to deploy its functional proteomics platform through a phased expansion focused on integration into oncology practices and Molecular Tumor Boards, beginning with patient populations where conventional biomarker guidance is limited. As targeted therapies and antibody drug conjugates continue expanding across tumor types, Ignite aims to become an essential infrastructure layer for therapy selection and longitudinal monitoring, advancing a model of care in which treatment decisions are guided by functional tumor biology from the outset. Ignite’s commercial positioning is supported by licensed intellectual property, an established Medicare PLA reimbursement pathway and ongoing clinical validation efforts.
Ignite’s platform is built on the premise that many targeted cancer therapies act at the protein level rather than the DNA level. While genomic and transcriptomic tests may indicate which proteins could be expressed in a tumor, Ignite’s Reverse Phase Protein Array (“RPPA”) platform is designed to measure protein expression and whether they are functionally active, a distinction that increasingly determines whether a patient would respond to modern targeted therapies.
Analyses from the I-SPY 2 clinical trial and related work have evaluated RPPA-based protein and phosphoprotein profiling as a source of potential therapy-response biomarkers. At the 2025 NCCN Annual Conference, Ignite presented I-SPY 2 data indicating that MHC-II protein expression, as measured using RPPA, outperformed the five PD-L1 assays evaluated in that analysis as a predictor of pembrolizumab response. Ignite’s platform is being validated through collaborations with leading cancer institutions including the Dana-Farber Cancer Institute at Harvard, Vanderbilt University Medical Center, and other National Cancer Institute-designated centers. In September 2025, Ignite entered a collaboration with Inova Health to apply its RPPA platform to up to 600 tumor samples from patients with late-stage gastrointestinal cancers. Protein-level activation data from these patients is being incorporated into Inova’s Molecular Tumor Board to guide treatment decisions in cases where no standard biomarker guidance exists.
Aditxt Co-founder and Chief Innovation Officer, Shahrokh Shabahang, DDS, MS, PhD added, “For many cancers, the key clinical question is not only what mutations are present, but whether the relevant signaling pathways are actually active in the tumor. That is where functional proteomics can add value. Ignite’s RPPA platform is designed to measure phospho- and total-protein biomarkers directly from biopsy material, which may provide information that complements genomic testing and helps support clinical decision-making, particularly in settings where conventional biomarker guidance is limited.”
Under the terms of the transaction documents, Aditxt acquired Ignite in a transaction providing 36,000 shares of Aditxt’s newly designated Series A-2 Convertible Preferred Stock, representing an aggregate stated value of $36.0 million, subject to the terms of the Certificate of Designation. Additional details regarding the transaction will be included in Aditxt’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.
About Ignite Proteomics, LLC
Ignite Proteomics delivers pathway-level protein analytics to guide precision oncology. Operating a CLIA-certified, CAP-accredited laboratory, Ignite's clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from limited biopsy material to support oncology research and clinical decision making.
About Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health.
Forward-Looking Statements
This press release includes “forward-looking statements,” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “aim,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “will,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding anticipated benefits of the acquisition, Ignite’s commercialization plans, the potential clinical utility of its platform, expected collaborations, publications, reimbursement, adoption, and international expansion. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company’s SEC filings, including Aditxt’s Annual Report on Form 10-K and any subsequent Form 10-Q filings, including the most recent filed on November 18, 2025. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260313909767/en/
Aditxt, Inc.
Investor Relations
ir@aditxt.com
Original: Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
chumfm
2日前
ErnieBilco
2日前
Overwatch
2週前
glenn1919
2月前
iHub News
3月前
TrendTrade2016
6月前
Monroe1
6月前
メールアドレスで登録
